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Abstract
Background: Premature cardiovascular disease in patients with chronic kidney disease (CKD) is not explained by traditional
risk factors and oxidative stress may contribute via endothelial and vascular dysfunction. We investigated the effect of
ascorbic acid on oxidative stress and vascular function in CKD patients compared with controls with hypertension (HTN).
Methods: A crossover study of intravenous saline and ascorbic acid was conducted. Biomarkers of oxidative stress were
measured, while pulse wave analysis and brachial flow-mediated dilatation were performed to assess large artery and
endothelial function.
Results: Twenty HTN and 30 CKD patients Stages 3–5 were recruited. Serum ascorbic acid was significantly lower in patients
with CKD. In both groups, ascorbic acid significantly increased total antioxidant potential and superoxide. Asymmetric
dimethylarginine (ADMA) was reduced significantly by ascorbic acid in the CKD group and on multivariate regression
analysis, age and the presence of CKD were predictors of ADMA response to ascorbic acid. Although no effect on FMD was
observed, central blood pressure and augmentation index were reduced significantly in both groups.
Conclusions: Ascorbic acid has pro- and antioxidant effects, reducing central blood pressure and augmentation index in
HTN and CKD. Ascorbic acid reduces serum ADMA in CKD, which may have longer-term benefits.
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Introduction
The risk of cardiovascular disease (CVD) is significantly elevated
in patients with chronic kidney disease (CKD) [1], with most
patients dying of a cardiovascular cause prior to requiring renal
replacement therapy. The prevalence of CVD can be explained
partly by shared risk factors, but these do not fully account for
the degree of observed CVD and its prevalence remains higher
after adjustment for age and comorbidities [2].
Some suggest that non-conventional risk factors specific to
CKD may explain this cardiovascular risk, including hyperphos-
phataemia, anaemia and inflammation. Oxidative stress is
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another risk factor characterized by an excess of reactive oxy-
gen species (ROS) and other oxidants, which cause derange-
ment in redox signalling, activating pathways that lead to
deleterious changes to vascular biology [3].
In vivo, this is demonstrated by evidence of endothelial dys-
function and by an increase in oxidative modification of macro-
molecules. For example, advanced oxidative protein products
(AOPPs), 8-hydroxydeoxyguanosine and F2-isoprostanes are all
elevated in CKD, while restoration of renal function by kidney
transplantation results in a significant reduction in these bio-
markers [4, 5]. Furthermore, plasma concentration of the nitric
oxide synthase (NOS) inhibitor asymmetric dimethylarginine
(ADMA) are increased in CKD, which causes increased ROS pro-
duction via uncoupling of endothelial NOS [6–8].
Previous studies have investigated the use of exogenous
antioxidants as therapy or as manipulators of redox homeosta-
sis to explore the mechanisms behind oxidative stress in CKD.
For example, antioxidant supplementation has been shown to
improve markers of oxidative stress and blood pressure (BP) in
animal models of CKD and hypertension (HTN) [9, 10]. In
humans, however, the data are conflicting, with some studies
showing certain benefits of antioxidant therapy in patients with
CKD [11, 12], and other studies finding no effect [13, 14].
In order to explore the mechanisms underlying vascular dys-
function in CKD and test the hypothesis that antioxidant
administration ameliorates oxidative stress and endothelial
dysfunction, we carried out a crossover study of intravenous
ascorbic acid and normal saline in a population of patients with




Subjects with CKD were recruited from general nephrology and
peritoneal dialysis (PD) clinics; subjects with HTN and normal
renal function were recruited from an HTN clinic. Participants
with diabetes, renovascular disease, liver disease or active
infection were excluded, or if there was a history of vitamin C
supplementation, renal stone disease or systemic oxalosis.
Haemodialysis patients were excluded, given the need for fore-
arm cannulation. The study was carried out in accordance with
the Declaration of Helsinki, approved by the West of Scotland
Research Ethics Committee, with informed consent received
from all participants. The study is registered with a clinical tri-
als registry (ISRCTN 31272864).
Study protocol
Participants attended in the morning, refraining from caffeine and
nicotine and after an overnight fast. Control infusions (100 mL
0.9% saline) and ascorbic acid (2000 mg in 100 mL 0.9% saline) were
given intravenously over 10 min and phlebotomy and vascular
function studies performed as described below. Phlebotomy was
carried out on a third occasion 1 h after ascorbic acid. Vascular
function studies and analyses were performed by a single opera-
tor. Participant details were removed from both flow-mediated
dilatation (FMD) and biomarker data to facilitate blinding.
Biochemical measurements
Baseline biochemistry was performed in an accredited biochem-
istry department. The estimated glomerular filtration rate (eGFR)
was calculated from serum creatinine using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) formula [16].
Biomarkers of oxidative stress
Blood samples were taken via an intravenous cannula contrala-
teral to the infusion arm after the control infusion of saline,
after ascorbic acid administration, and 1 h after ascorbic acid
administration. Samples were analysed for a panel of bio-
markers of oxidative stress as described below.
A colorimetric assay was used to measure 8-iso-prostaglan-
din F2a (F2-isoprostane) as a marker of lipid peroxidation (Direct
8-iso-Prostaglandin F2a Enzyme Immunoassay Kit, Assay
Designs, Ann Arbor, MI, USA). The assay has an intra- and inter-
assay coefficient of variation (CV) of 5–10%, with a cross-reactiv-
ity to other eicosanoids of <5%. The ratio of glutathione to
glutathione disulphide (GSH/GSSG) was taken as a measure of
reduced glutathione availability, and this was measured using a
colorimetric assay (Bioxytech GSH/GSSG-412, OxisResearch,
Portland, OR, USA). Intra- and interassay CVs for GSH were 0.96
and 3.11% and for GSSG were 6.45 and 7.61%, respectively. Total
antioxidant potential (TAP) was measured using a quantitative
colorimetric assay (Bioxytech AOP-450 Quantitative Assay for
Total Antioxidant Potential, OxisResearch). The intra- and inter-
assay CVs were 0.7 and 1.5%, respectively [17]. High-perform-
ance liquid chromatography (HPLC) was used to measure both
ascorbic acid and ADMA in plasma. Intra- and interassay CVs
were 1.9 and 2.5% for ADMA [18] and 1.0 and 3.7% for ascorbic
acid. Whole blood samples were also taken and underwent elec-
tron paramagnetic resonance spectrometry (EPR) to measure
the rate of superoxide (O2
) production (E-scan EPR system,
Bruker, Billerica, MA, USA).
Assessment of endothelial function
Endothelial function was assessed by measuring the dilator
response of the brachial artery to increased blood flow induced
by reactive hyperaemia, termed FMD. Longitudinal recordings
of the brachial artery were taken using a 7-MHz ultrasound
transducer and a Siemens Accuson Sequoia ultrasound system
(Siemens, Berlin, Germany). Recordings were made at baseline,
after 5 min inflation of a BP cuff and after 25 mg sublingual glyc-
eryl trinitrate (GTN). FMD was performed according to the 2002
guidelines [19] and recent update [20]. Image analysis was per-
formed offline using bespoke software (Brachial Analyzer 5,
Medical Imaging Applications, Coralville, IA, USA). Absolute
FMD was calculated as the baseline diameter subtracted from
the peak diameter following cuff inflation, while the percentage
of FMD was calculated as the absolute FMD divided by the base-
line diameter. The intra-operator CV of FMD was 14.68%.
Assessment of arterial function
Arterial properties were evaluated using the SphygmoCor Vx sys-
tem (Atcor Medical, West Ryde, NSW, Australia) of applanation
tonometry. The augmentation index (Aix) was measured at the
radial artery over 15 s and corrected to a heart rate of 75 bpm to
derive the adjusted Aix (adjAix). Central BP was derived from the
central pulse wave by means of a Fourier transformation of the
measured radial pulse wave. Pulse wave velocity (PWV) was
measured by measuring the distance between the right carotid
and femoral pulses (via the umbilicus) and then the time between
the R wave of the electrocardiogram and the upstroke of the arte-
rial waveform was measured at each pulse. The carotid to femo-
ral PWV is equal to the distance between the two pulses divided
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by the transit time. The intra-operator CVs for adjAix and PWV
were 5.25 and 4.83%, respectively.
Statistics
In a sample size calculation, based on a previous study where
FMD was improved by ascorbic acid in renal transplant recipi-
ents [12], 26 patients with CKD would need to be examined to
demonstrate a clinically relevant improvement in FMD from the
saline infusion to the ascorbic acid infusion of >2% with a
standard deviation of 3%, power of 90%, a¼ 0.05 and with a
paired comparison.
Between-group data were compared using a two-tailed
Student’s t-test or Mann–Whitney U-test. For related data,
a paired samples Student’s t-test or Wilcoxon’s test was used.
P< 0.05 was considered significant.
A comparison of response to ascorbic acid between the CKD
and HTN groups was made using a difference in differences
analysis (DID): a regression analysis was performed with the
mean of the measured biomarker as the dependent variable
and the treatment, time point and treatment  time point as
predictor variables.
The relationship between the change in ADMA following
ascorbic acid and the presence of CKD was examined via regres-
sion analysis initially with a univariate analysis (simple correla-
tion) and then stepwise multiple linear regression analysis,
with inclusion of variables at P < 0.05. Given the small sample
size, covariates were entered into the multivariate model based
on published literature on ADMA regulation [21–24]. All statisti-
cal testing was performed using SPSS version 22.0 (IBM,
Armonk, NY, USA).
Results
Thirty subjects with CKD (22 CKD Stages 3–5; 8 PD) and 20
subjects with HTN were recruited, with eGFRs of 22.4612.6 mL/
min/1.73 m2 and 94.4611.7 mL/min/1.73 m2, respectively
(P< 0.001). The two groups were well matched for age, body
mass index (BMI), smoking status and medication history, but
BP was higher in the HTN group (Table 1).
Biomarkers
Table 2 and Figure 1 show the baseline and change in bio-
markers of oxidative stress after ascorbic acid in each group.
Baseline ascorbic acid was lower in patients with CKD than
in HTN (22.5627.5 versus 44.0614.1 mmol/L; P¼ 0.023), while
ADMA (0.6160.14 versus 0.4860.07 mmol/L; P< 0.001) and TAP
(0.666 0.15 mM Trolox versus 0.586 0.10 mM Trolox; P¼ 0.027)
were higher. At baseline there were no between-group differen-
ces in F2-isoprostanes (1036.96 1048.6 versus 899.06 643.0 pg/
mL; P¼ 0.61), GSH:GSSG (91.16 251.9 versus 140.06448.8;
P¼ 0.75) or O2 production (0.506 0.29 versus 0.3760.95 arbitrary
units; P¼ 0.08).
Serum ascorbic acid levels rose immediately after its admin-
istration, before falling, albeit to higher than baseline, at
the third time point (22.5, 705.7 and 483.2 versus 44.0, 552.9 and
297.5 mmol/L; P< 0.001). In CKD, TAP changed from 0.6660.15 to
1.2460.20 (P< 0.001) to 1.116 0.22 mM Trolox (P< 0.001), while
O2 production changed from 0.5060.29 to 0.6360.22 (P¼ 0.038)
to 0.5560.18 arbitrary units (P¼ 0.42). In HTN, TAP changed
from 0.5860.10 to 1.156 0.22 (P< 0.001) to 0.856 0.14 mM Trolox
(P< 0.001) and O2
 changed from 0.3760.10 to 0.5060.14
(P¼ 0.005) to 0.4360.10 arbitrary units (P¼ 0.007).
There was no change in F2-isoprostanes observed in
CKD (1036.96 1048.6, 1015.36994.3, 855.96 383.5 pg/mL; P¼ 0.93)
or HTN (899.06643.0, 834.96 651.0, 728.66463.8 pg/mL; P¼ 0.63),
nor was there a change in GSH:GSSG in CKD (91.16251.9, 51.96
92.6, 45.2682.0; P¼ 0.30) or HTN (140.06448.8, 111.36390.4,
41.66 74.7; P¼ 0.84).
After administration of ascorbic acid there was a reduction
in ADMA in the CKD group (0.6160.14 to 0.5860.14 mmol/L;
P¼ 0.039), but not the HTN group (0.4860.07 to 0.5160.07 mmol/
L; P¼ 0.36), which reached statistical significance in the second
but not the third phlebotomy time point. The degree of change
Table 1. Baseline parameters in both cohorts
Parameter HTN CKD P-value
Age (years) 56610 596 14 0.34
BMI (kg/m2) 30.965.4 28.16 6.7 0.13
Peripheral BP (mmHg) 150/95617/10 141/826 15/10 0.04*
Mean arterial BP (mmHg) 112612 101.66 10.2 0.002*
Creatinine (mmol/L) 71611 3596 274 <0.001*
eGFR (mL/min/1.73m2) 94.4611.7 22.46 12.6 <0.001*
Angiotensin-converting
enzyme inhibitor, n (%)
9 (45) 15 (50) 0.62
Angiotensin receptor
blocker, n (%)
6 (30) 7 (23) 0.60
Beta-blocker, n (%) 3 (15) 10 (33) 0.15
Calcium channel
blocker, n (%)
10 (50) 15 (50) 1.00
Statin, n (%) 6 (30) 16 (53) 0.10
Allopurinol, n (%) 2 (10) 10 (33) 0.06
Spironolactone, n (%) 2 (10) 0 (0) 0.07
Current smoker, n (%) 4 (20) 6 (20) 0.62
*Indicate a significant difference.
Table 2. Results of biomarker assays before and after administration of ascorbic acid
Parameter
HTN CKD
Before After P-value Before After P-value
Ascorbic acid (mmol/L) 44.06 14.1a 552.96 127.9b <0.001 22.56 27.5a 705.76 347.5b <0.001
ADMA (mmol/L) 0.486 0.07 0.516 0.07 0.36 0.616 0.14 0.586 0.14 b 0.039
F2-isoprostanes (pg/mL) 899.06 643.0 834.96 651.0 0.63 1036.96 1048.6 1015.36 994.3 0.93
TAP (mM Trolox) 0.586 0.10a 1.156 0.22b <0.001 0.666 0.15a 1.246 0.20b <0.001
GSH:GSSG ratio 140.06 448.8 111.36 390.4 0.84 91.16 251.9 51.96 92.6 0.30
O2 production (arbitrary units) 0.376 0.10 0.506 0.14
b 0.005 0.506 0.29 0.636 0.22b 0.038
aIndicates parameters where there was a significant difference in baseline values between the two groups in an independent samples t-test.
bThis, along with P-values, refers to a paired samples t-test comparing values measured before and after ascorbic acid.
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in ADMA was also significantly different between the two
groups (–0.0460.09 versus 0.0260.06 mmol/L; P¼ 0.013).
In a DID analysis, there was no between-group differences in
the response to ascorbic acid of ascorbic acid (174.3 mmol/L;
P¼ 0.12), ADMA (0.06 mmol/L; P¼ 0.22), F2-isoprostanes (42.4 pg/
mL; P¼ 0.91), TAP (0.01 mM Trolox; P¼ 0.91), GSH:GSSH ratio
(26.2; P¼ 0.84) or O2 (0.00 arbitrary units; P¼ 0.99).
A regression analysis was carried out on the determinants of
the response of ADMA to ascorbic acid with age, presence of
CKD, BMI, BP and gender entered into the model (Table 3). Due
to the small sample size, only a limited number of variables
were entered. These variables were included because of pub-
lished data suggesting their involvement in ADMA regulation
[21–24] and first entered into a simple regression analysis. In a
multiple regression analysis, age was positively associated with
a change in ADMA in response to ascorbic acid and the presence
of CKD was negatively associated, while BMI, BP and gender
were not significant predictors (R2 ¼ 0.21, P¼ 0.008).
Arterial stiffness
Figure 2 and Table 4 demonstrate measurements of vascular
function studies before and after ascorbic acid.
Baseline central BP was higher in the HTN group (132/
85615/11 versus 142/97618/10 mmHg; P¼ 0.042) but there was
no difference in adjAix (25.668.0 versus 24.4612.3%; P¼ 0.70).
PWV was higher in the CKD group (10.26 2.5 versus 8.661.7 m/
s; P¼ 0.022).
Following administration of ascorbic acid, central BP fell in
both CKD (132/85615/11 to 120/756 21/11 mmHg; P¼ 0.005) and
A B
C D
Fig. 1. Change in (A) ascorbic acid, (B) O2 production, (C) ADMA and (D) TAP in both groups after administration of ascorbic acid. Measurements of biomarkers of oxida-
tive stress made in both groups are shown at (1) baseline, (2) after ascorbic acid and (3) at 1 h after ascorbic acid.
*Indicates a significant difference (P<0.05) in comparison with baseline.
Table 3. Simple and multiple linear regression analysis of the predictors of the change in ADMA in nanomoles in response to ascorbic acid
administration.
Predictor Increment
Simple regression Multiple regression
B 95% CI P-value B 95% CI P-value
CKD 60.81 108.08 to 13.54 0.01 70.89 119.91 to 21.86 0.006
Age (years) 10 14.70 4.94–34.35 0.14 19.96 0.72–39.19 0.042
Central systolic BP (mmHg) 10 0.69 16.45–15.07 0.93
BMI (kg/m2) 1 2.05 1.80–5.90 0.29
Male 1.51 49.64–52.67 0.95
CI, confidence interval.
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Table 4. Results of vascular function tests before and after administration of ascorbic acid
Parameter
HTN CKD
Before After P-value Before After P-value
Central BP (mmHg) 142/976 18/10a 130/81625/15b 0.002 132/85615/12a 120/75621/11b 0.005
adjAix (%) 24.46 12.3a 17.6611.3b <0.001 25.668.0a 15.8610.4b <0.001
PWV (m/s) 8.66 1.7a 8.461.5 0.28 10.262.5a 9.763.0 0.11
Brachial artery diameter (mm) 4.716 0.81 5.1560.84b <0.001 4.4060.67 4.7660.87b <0.001
FMD (mm) 0.196 0.07 0.2560.14 0.12 0.2060.11 0.2760.15 0.10
FMD (%) 4.136 1.99 5.0863.00 0.31 4.8963.16 5.7763.62 0.35
GTN-mediated dilatation (mm) 0.556 0.25 0.3260.23b <0.001 0.6160.16 0.3360.22 b <0.001
GTN-mediated dilatation (%) 12.306 5.91 6.6364.91b <0.001 14.1764.66 7.6065.39 b <0.001
aIndicates parameters where there was a significant difference in baseline values between the two groups in an independent samples t-test.
bThis, along with P-values, refers to a paired samples t-test comparing values measured before and after ascorbic acid.
Fig. 2. Change in (A) central BP and (B) Aix in both HTN and CKD.
*Indicate a significant difference (P<0.05) occurring after ascorbic acid. SAL, normal saline; AA, ascorbic acid; NS, not significant.
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HTN (142/97618/10 to 130/81625/15 mmHg; P¼ 0.002). A reduc-
tion in adjAix was seen in CKD (25.668.0 to 15.8610.4%;
P< 0.001) and HTN (24.4612.3 to 17.6611.3%; P< 0.001), but no
change in PWV was observed in either group.
In a DID analysis, there was no between-group difference in
response to ascorbic acid of central systolic BP (0.62 mmHg
P¼ 0.94), adjAix (3.0%, P¼ 0.49) or PWV (0.29 m/s, P¼ 0.77).
Endothelial dysfunction
At baseline, no significant difference was observed in the diam-
eter of the brachial artery between the HTN and CKD groups
(4.716 0.81 versus 4.4060.67 mm; P¼ 0.18) (Table 4). Neither
was there a between-group difference in FMD in either absolute
(0.196 0.07 versus 0.1960.12 mm; P¼ 0.27) or proportional
(4.136 1.99 versus 4.896 3.16%; P¼ 0.51) terms.
In the HTN group, after administration of ascorbic acid, FMD
changed from 0.1960.07 to 0.256 0.14 (P¼ 0.12) and the per-
centage FMD changed from 4.1361.99 to 5.0863.00 (P¼ 0.31). In
the CKD group FMD changed from 0.206 0.11 to 0.2760.15 mm
(P¼ 0.10) and proportional FMD changed from 4.8963.16 to
5.7763.62 (P¼ 0.35) after ascorbic acid. There was a significant
reduction in endothelial independent dilatation after ascorbic
acid administration, in both the HTN group (12.306 5.91 versus
6.6364.91%; P< 0.001) and the CKD group (14.1764.66 versus
7.6065.39%; P< 0.001).
In a DID analysis there was no between-group difference in
the change in FMD after ascorbic acid (0.43 mm, P¼ 0.75)
Discussion
Oxidative stress is a state of disturbed redox signalling due to
an excess of ROS and derivatives and a consequent depletion of
cardioprotective signalling molecules such as nitric oxide (NO).
Understanding the mechanisms underlying these processes
may lead to the development of novel therapeutics that will
reduce the burden of CVD in patients with CKD.
In both cohorts there was a numerical increase in FMD follow-
ing administration of ascorbic acid, which did not reach statisti-
cal significance. Results of previous studies into the vascular
effects of ascorbic acid are conflicting: Cross et al. [13] found no
improvement in FMD after parenteral administration of ascorbic
acid, but Williams et al. [12] found improvement in endothelium-
dependent vasodilatation after ascorbic acid supplementation in
a cohort of transplant patients with mild impairment of kidney
function. In an earlier study by Taddei et al. [25], ascorbic acid
augmented the increase in forearm blood flow caused by acetyl-
choline but not sodium nitroprusside, and this effect was
reversed by NOS inhibition, suggesting that ascorbic acid
increases endothelium-dependent vasodilatation in an NO-
dependent manner. That no effect on FMD was observed in this
study could be attributed to the method of administration, given
as an intravenous pulse rather than an intra-arterial infusion or
oral supplement. It is also possible that the studied population
was of inherently high cardiovascular risk compared with other
studies, as demonstrated by the lower FMD and high PWV at
baseline, which may result in more resistant vascular
dysfunction.
The presence of CKD was associated with a decrease in
ADMA after administration of ascorbic acid, echoing the results
of earlier studies that have shown a reduction in ADMA levels
in patients with CKD supplemented with vitamin E [26]. Given
that ADMA is a significant predictor of cardiovascular outcome
[27], this may represent an important mechanism by which
antioxidants exert a beneficial cardiovascular effect, which
should be explored in a larger randomized placebo-controlled
study.
Conversely, ascorbic acid reduced central BP in both the HTN
and CKD groups by 12/15 and 12/10 mmHg, respectively, and
this was associated with a reduction in Aix. This was also
reflected in an increase in the diameter of the brachial artery at
the baseline stage of FMD, suggesting that this might have
occurred due to systemic vasodilatation. Juraschek et al. [28]
previously conducted a meta-analysis of the effect of longitudi-
nal ascorbic acid supplementation on BP, finding that systolic
and diastolic BPs were reduced by 4.85 and 1.67 mmHg,
respectively.
It is interesting that the vascular effects of ascorbic acid are
little different in HTN compared with CKD and that there was
little difference in either biomarkers of oxidative stress or
endothelial dysfunction at baseline. While baseline FMD in the
CKD group was similar to other studies in this cohort [29–31],
in the HTN group, FMD was 4.13%, which is lower than in
many other studies in similar populations. Having been
recruited from a tertiary referral BP clinic, it is possible that
this represents a population with higher cardiovascular risk
than in previously studied populations with HTN and normal
renal function [32]. Similarly, although the two study groups
were well matched for age, BMI, smoking status and medica-
tion history, BP was higher in the HTN group. In the absence
of any confounding factors, such as diabetes or pre-existing
coronary artery disease, it is possible that such higher BP
might offset the differences in vascular disease occurring due
to renal impairment.
There are limitations to this study that should be acknowl-
edged. Patients with diabetes were excluded to examine the
specific effect of uraemia on vascular function and oxidative
stress, but it could be argued that this limits the applicability of
these data to those with diabetes. Bias may also have been
introduced by the need for participants to undergo a prolonged
study visit that may select out healthier patients. Vascular
function studies and biomarkers are evaluated on a single day
and repeated arterial occlusion and exposure to GTN may con-
found the interpretation of brachial artery ultrasound measure-
ments. Nevertheless, performing the study on a single day
removes the confounding effect of day-to-day variability from
the results. Serum levels of ascorbic acid rose to very high lev-
els during the study, higher than would be predicted in healthy
subjects [33] or during oral supplementation [34], such that the
relevance of the effects of such levels of antioxidant could be
questioned, although it has previously been shown that supra-
physiological doses of ascorbic acid are required to manipulate
vascular function [35]. Furthermore, the sample size calculation
was based on between-group differences in FMD, so differences
in other measured parameters could be due to chance rather
than true between-group differences. Indeed, the study is lim-
ited in large part by its small sample size and should be viewed
as a proof-of-concept study. Nevertheless, our findings demon-
strate that more robust studies with well-characterized cohorts
are required to more precisely measure the oxidative stress
associated specifically with uraemia, separate from other risk
factors.
In summary, in comparison with matched hypertensive con-
trols, CKD patients have ascorbic acid deficiency but otherwise
similar levels of oxidative stress and endothelial dysfunction. In
both CKD and in a high-risk hypertensive population, parenteral
ascorbic acid reduces central BP and Aix in a manner independ-
ent of endothelial function. Further studies are required to
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assess the effects of chronic ascorbic acid on vascular function
in these populations.
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